Dyspnea, Relative Youth and Low Daily Doses of Opioids Predict Increased Opioid Dosage in the Last Week of a Terminal Cancer Patient's Life
Authors:
Open Access
- 23 September 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 44 (11) , 1082-1087
Abstract
Most cancer patients become increasingly anxious toward the end of their life. The objective of this study was to identify predictors of increased opioid dosage in the last week of a terminal cancer patient's life. We retrospectively reviewed charts of patients who died in our palliative care unit. We assigned the patients to increased group or decreased group according to changes in oral morphine equivalent dosage in their last 7 days. Logistic regression analysis was used to identify predictors of increased oral morphine equivalent dosage. We analyzed data of 158 patients (female: 43.7%, median age: 64 years). The median oral morphine equivalent dosages on Days 7 and 1 before death were 50 mg (interquartile range: 24–122) and 61 mg (28–129), respectively. Independent predictors of increased oral morphine equivalent dosage included dyspnea (odds ratio: 11.5, 95% confidence interval: 4.98–28.83, P < 0.01), age <65 years (odds ratio: 2.3, 95% confidence interval: 1.04–5.26, P = 0.04) and oral morphine equivalent dosage <50 mg on Day 7 before death (odds ratio: 3.7, 95% confidence interval: 1.68–8.89, P < 0.01). The median oral morphine equivalent dosages on Days 7 and 1 before death were 48 mg (interquartile range: 20–126) and 75 mg (36–170) in patients with dyspnea, and 50 mg (25–120) and 57 mg (25–124) in patients with pain, respectively. Dyspnea, relative youth and oral morphine equivalent dosage <50 mg on Day 7 before death were predictive of increased oral morphine equivalent dosage in the last 7 days. Our findings may help oncologists to more accurately inform patients about expected opioid requirements and thus relieve their end-of-life anxiety.Keywords
This publication has 33 references indexed in Scilit:
- Epigenetic transcriptional activation of monocyte chemotactic protein 3 contributes to long-lasting neuropathic painBrain, 2013
- Home Palliative Care -Analysis of 553 Terminal Cancer Cases-Haigan, 2009
- Pharmacologic Intervention for Cancer-Related DyspneaJournal of Clinical Oncology, 2008
- Opioids and the Management of Chronic Severe Pain in the Elderly: Consensus Statement of an International Expert Panel with Focus on the Six Clinically Most Often Used World Health Organization step III Opioids (Buprenorphine, Fentanyl, Hydromorphone, Methadone, Morphine, Oxycodone)Pain Practice, 2008
- Interventions for Alleviating Cancer-Related Dyspnea: A Systematic ReviewJournal of Clinical Oncology, 2008
- Evidence-informed management of chronic low back pain with cognitive behavioral therapyThe Spine Journal, 2008
- Opioid Use and Survival at the End of Life: A Survey of a Hospice PopulationJournal of Pain and Symptom Management, 2006
- Midazolam as Adjunct Therapy to Morphine in the Alleviation of Severe Dyspnea Perception in Patients with Advanced CancerJournal of Pain and Symptom Management, 2006
- Cancer Pain and Psychosocial FactorsJournal of Pain and Symptom Management, 2002
- Mood states of oncology outpatients: Does pain make a difference?Journal of Pain and Symptom Management, 1995